Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 635680, 9 pages
http://dx.doi.org/10.1155/2008/635680
Review Article

Protective Actions of PPAR- Activation in Renal Endothelium

1Department of Vascular Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
2Department of Internal Medicine, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands

Received 15 September 2008; Accepted 8 December 2008

Academic Editor: Nigel Brunskill

Copyright © 2008 Peter E. Westerweel and Marianne C. Verhaar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Guan and M. D. Breyer, “Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease,” Kidney International, vol. 60, no. 1, pp. 14–30, 2001. View at Publisher · View at Google Scholar
  2. P. A. Sarafidis and G. L. Bakris, “Protection of the kidney by thiazolidinediones: an assessment from bench to bedside,” Kidney International, vol. 70, no. 7, pp. 1223–1233, 2006. View at Publisher · View at Google Scholar
  3. K. Haraguchi, H. Shimura, and T. Onaya, “Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)γ activators,” Clinical and Experimental Nephrology, vol. 7, no. 1, pp. 27–32, 2003. View at Publisher · View at Google Scholar
  4. A. Benigni, C. Zoja, S. Tomasoni et al., “Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-? agonist: molecular mechanism of the antiproteinuric effect of pioglitazone,” Journal of the American Society of Nephrology, vol. 17, no. 6, pp. 1624–1632, 2006. View at Publisher · View at Google Scholar
  5. L.-J. Ma, C. Marcantoni, M. F. Linton, S. Fazio, and A. B. Fogo, “Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats,” Kidney International, vol. 59, no. 5, pp. 1899–1910, 2001. View at Publisher · View at Google Scholar
  6. A. Sivarajah, P. K. Chatterjee, N. S. A. Patel et al., “Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury,” The American Journal of Nephrology, vol. 23, no. 4, pp. 267–276, 2003. View at Publisher · View at Google Scholar
  7. P. E. Westerweel, K. den Ouden, T. Q. Nguyen, R. Goldschmeding, J. A. Joles, and M. C. Verhaar, “Amelioration of anti-Thy1-glomerulonephritis by PPAR-γ agonism without increase of endothelial progenitor cell homing,” The American Journal of Physiology, vol. 294, no. 2, pp. F379–F384, 2008. View at Publisher · View at Google Scholar
  8. M. Matsuyama, R. Yoshimura, T. Hase et al., “Expression of peroxisome proliferator-activated receptor-? in renal ischemia-reperfusion injury,” Transplantation Proceedings, vol. 37, no. 4, pp. 1684–1685, 2005. View at Publisher · View at Google Scholar
  9. R. Yoshimura, M. Matsuyama, Y. Segawa et al., “Study of peroxisome proliferator-activated receptor (PPAR)-? in renal ischemia-reperfusion injury,” Transplantation Proceedings, vol. 36, no. 7, pp. 1946–1948, 2004. View at Publisher · View at Google Scholar
  10. Y. Guan, Y. Zhang, A. Schneider, L. Davis, R. M. Breyer, and M. D. Breyer, “Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature,” The American Journal of Physiology, vol. 281, no. 6, pp. F1036–F1046, 2001. View at Google Scholar
  11. N. Yamanaka and A. Shimizu, “Role of glomerular endothelial damage in progressive renal disease,” Kidney and Blood Pressure Research, vol. 22, no. 1-2, pp. 13–20, 1999. View at Publisher · View at Google Scholar
  12. M. E. J. Reinders, T. J. Rabelink, and D. M. Briscoe, “Angiogenesis and endothelial cell repair in renal disease and allograft rejection,” Journal of the American Society of Nephrology, vol. 17, no. 4, pp. 932–942, 2006. View at Publisher · View at Google Scholar
  13. D. A. Long, W. Mu, K. L. Price, and R. J. Johnson, “Blood vessels and the aging kidney,” Nephron Experimental Nephrology, vol. 101, no. 3, pp. e95–e99, 2005. View at Publisher · View at Google Scholar
  14. J. P. Garg and G. L. Bakris, “Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease,” Vascular Medicine, vol. 7, no. 1, pp. 35–43, 2002. View at Publisher · View at Google Scholar
  15. G. L. Bakris, “Clinical importance of microalbuminuria in diabetes and hypertension,” Current Hypertension Reports, vol. 6, no. 5, pp. 352–356, 2004. View at Publisher · View at Google Scholar
  16. S. Gschwend, H. Buikema, G. Navis, R. H. Henning, D. de Zeeuw, and R. P. E. van Dokkum, “Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat,” Journal of the American Society of Nephrology, vol. 13, no. 12, pp. 2909–2915, 2002. View at Publisher · View at Google Scholar
  17. A. Shimizu, H. Kitamura, Y. Masuda, M. Ishizaki, Y. Sugisaki, and N. Yamanaka, “Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis,” The American Journal of Pathology, vol. 151, no. 5, pp. 1231–1239, 1997. View at Google Scholar
  18. L. Iruela-Arispe, K. Gordon, C. Hugo et al., “Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis,” The American Journal of Pathology, vol. 147, no. 6, pp. 1715–1727, 1995. View at Google Scholar
  19. Y. Masuda, A. Shimizu, T. Mori et al., “Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis,” The American Journal of Pathology, vol. 159, no. 2, pp. 599–608, 2001. View at Google Scholar
  20. K. Miyamoto, Y. Kitamoto, H. Tokunaga et al., “Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat,” Laboratory Investigation, vol. 84, no. 9, pp. 1126–1136, 2004. View at Publisher · View at Google Scholar
  21. T. Ostendorf, U. Kunter, F. Eitner et al., “VEGf165 mediates glomerular endothelial repair,” The Journal of Clinical Investigation, vol. 104, no. 7, pp. 913–923, 1999. View at Publisher · View at Google Scholar
  22. D.-H. Kang, J. Hughes, M. Mazzali, G. F. Schreiner, and R. J. Johnson, “Impaired angiogenesis in the remnant kidney model—part II: vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function,” Journal of the American Society of Nephrology, vol. 12, no. 7, pp. 1448–1457, 2001. View at Google Scholar
  23. D. H. Kang, A. H. Joly, S. W. Oh et al., “Impaired angiogenesis in the remnant kidney model—part I: potential role of vascular endothelial growth factor and thrombospondin-1,” Journal of the American Society of Nephrology, vol. 12, no. 7, pp. 1434–1447, 2001. View at Google Scholar
  24. M. B. Rookmaaker, H. Tolboom, R. Goldschmeding, J.-J. Zwaginga, T. J. Rabelink, and M. C. Verhaar, “Bone marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy,” Blood, vol. 99, no. 3, p. 1095, 2002. View at Publisher · View at Google Scholar
  25. M. B. Rookmaaker, A. M. Smits, H. Tolboom et al., “Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis,” The American Journal of Pathology, vol. 163, no. 2, pp. 553–562, 2003. View at Google Scholar
  26. M. B. Rookmaaker, M. C. Verhaar, A. J. Van Zonneveld, and T. J. Rabelink, “Progenitor cells in the kidney: biology and therapeutic perspectives,” Kidney International, vol. 66, no. 2, pp. 518–522, 2004. View at Publisher · View at Google Scholar
  27. E. L. Lagaaij, G. F. Cramer-Knijnenburg, F. J. van Kemenade, L. A. van Es, J. A. Bruijn, and J. H. J. M. van Krieken, “Endothelial cell chimerism after renal transplantation and vascular rejection,” The Lancet, vol. 357, no. 9249, pp. 33–37, 2001. View at Publisher · View at Google Scholar
  28. H. Peters, U. Daig, S. Martini et al., “No mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis,” Kidney International, vol. 64, no. 2, pp. 509–518, 2003. View at Publisher · View at Google Scholar
  29. B. Li, T. Morioka, M. Uchiyama, and T. Oite, “Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model,” Kidney International, vol. 69, no. 2, pp. 323–330, 2006. View at Publisher · View at Google Scholar
  30. H. Uchimura, T. Marumo, O. Takase et al., “Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 997–1004, 2005. View at Publisher · View at Google Scholar
  31. I. Barroso, M. Gurnell, V. E. F. Crowley et al., “Dominant negative mutations in human PPAR? associated with severe insulin resistance, diabetes mellitus and hypertension,” Nature, vol. 402, no. 6764, pp. 880–883, 1999. View at Publisher · View at Google Scholar
  32. P. D. G. Miles, Y. Barak, W. He, R. M. Evans, and J. M. Olefsky, “Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency,” The Journal of Clinical Investigation, vol. 105, no. 3, pp. 287–292, 2000. View at Publisher · View at Google Scholar
  33. T. Yamauchi, J. Kamon, H. Waki et al., “The mechanisms by which both heterozygous peroxisome proliferator-activated receptor ? (PPAR?) deficiency and PPAR? agonist improve insulin resistance,” The Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245–41254, 2001. View at Publisher · View at Google Scholar
  34. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPAR? is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar
  35. S. Z. Duan, C. Y. Ivashchenko, S. E. Whitesall et al., “Hypotension, lipodystrophy, and insulin resistance in generalized PPAR?-deficient mice rescued from embryonic lethality,” The Journal of Clinical Investigation, vol. 117, no. 3, pp. 812–822, 2007. View at Publisher · View at Google Scholar
  36. C. J. Nicol, M. Adachi, T. E. Akiyama, and F. J. Gonzalez, “PPARγ in endothelial cells influences high fat diet-induced hypertension,” The American Journal of Hypertension, vol. 18, no. 4, pp. 549–556, 2005. View at Publisher · View at Google Scholar
  37. A. M. Beyer, G. L. Baumbach, C. M. Halabi et al., “Interference with PPAR? signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling,” Hypertension, vol. 51, no. 4, pp. 867–871, 2008. View at Publisher · View at Google Scholar
  38. R. K. Semple, A. Meirhaeghe, A. J. Vidal-Puig et al., “A dominant negative human peroxisome proliferator-activated receptor (PPAR)a is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms,” Endocrinology, vol. 146, no. 4, pp. 1871–1882, 2005. View at Publisher · View at Google Scholar
  39. Y. Fukunaga, H. Itoh, K. Doi et al., “Thiazolidinediones, peroxisome proliferator-activated receptor ? agonists, regulate endothelial cell growth and secretion of vasoactive peptides,” Atherosclerosis, vol. 158, no. 1, pp. 113–119, 2001. View at Publisher · View at Google Scholar
  40. S. T. de Dios, K. M. Hannan, R. J. Dilley, M. A. Hill, and P. J. Little, “Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells,” Journal of Diabetes and Its Complications, vol. 15, no. 3, pp. 120–127, 2001. View at Publisher · View at Google Scholar
  41. H. K. Hong, Y. M. Cho, K.-H. Park, C.-T. Lee, H. K. Lee, and K. S. Park, “Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells,” Diabetes Research and Clinical Practice, vol. 62, no. 1, pp. 1–8, 2003. View at Publisher · View at Google Scholar
  42. W. H.-H. Sheu, H.-C. Ou, F.-P. Chou, T.-M. Lin, and C.-H. Yang, “Rosiglitazone inhibits endothelial proliferation and angiogenesis,” Life Sciences, vol. 78, no. 13, pp. 1520–1528, 2006. View at Publisher · View at Google Scholar
  43. S. Goetze, F. Eilers, A. Bungenstock et al., “PPAR activators inhibit endothelial cell migration by targeting Akt,” Biochemical and Biophysical Research Communications, vol. 293, no. 5, pp. 1431–1437, 2002. View at Publisher · View at Google Scholar
  44. X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” The Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999. View at Publisher · View at Google Scholar
  45. F. Biscetti, E. Gaetani, A. Flex et al., “Selective activation of peroxisome proliferator-activated receptor (PPAR)a and PPAR? induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism,” Diabetes, vol. 57, no. 5, pp. 1394–1404, 2008. View at Publisher · View at Google Scholar
  46. M. Artwohl, T. Hölzebein, C. Fürnsinn et al., “Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells,” Thrombosis and Haemostasis, vol. 93, no. 5, pp. 810–815, 2005. View at Publisher · View at Google Scholar
  47. K. M. Hannan, R. J. Dilley, S. T. de Dios, and P. J. Little, “Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 762–768, 2003. View at Publisher · View at Google Scholar
  48. D. Bishop-Bailey and T. Hla, “Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2,” The Journal of Biological Chemistry, vol. 274, no. 24, pp. 17042–17048, 1999. View at Publisher · View at Google Scholar
  49. A.-L. Levonen, D. A. Dickinson, D. R. Moellering, R. T. Mulcahy, H. J. Forman, and V. M. Darley-Usmar, “Biphasic effects of 15-deoxy-Δ12,14-prostaglandin J2 on glutathione induction and apoptosis in human endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 11, pp. 1846–1851, 2001. View at Publisher · View at Google Scholar
  50. H. Migita and J. Morser, “15-deoxy-Δ12,14-postaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-α but not peroxisome proliferator-activated receptor-γ in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-α-induced gene expression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 4, pp. 710–716, 2005. View at Publisher · View at Google Scholar
  51. P.-H. Huang, M. Sata, H. Nishimatsu, M. Sumi, Y. Hirata, and R. Nagai, “Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice,” Biomedicine and Pharmacotherapy, vol. 62, no. 1, pp. 46–52, 2008. View at Publisher · View at Google Scholar
  52. K. Chu, S.-T. Lee, J.-S. Koo et al., “Peroxisome proliferator-activated receptor-?-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia,” Brain Research, vol. 1093, no. 1, pp. 208–218, 2006. View at Publisher · View at Google Scholar
  53. T. Murata, S. He, M. Hangai et al., “Peroxisome proliferator-activated receptor-? ligands inhibit choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309–2317, 2000. View at Google Scholar
  54. D. Panigrahy, S. Singer, L. Q. Shen et al., “PPAR? ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002. View at Publisher · View at Google Scholar
  55. V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, “PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer,” Neoplasia, vol. 7, no. 3, pp. 294–301, 2005. View at Publisher · View at Google Scholar
  56. M. C. Verhaar and T. J. Rabelink, “Endothelial function: strategies for early intervention,” Cardiovascular Drugs and Therapy, vol. 12, supplement 1, pp. 125–134, 1998. View at Publisher · View at Google Scholar
  57. D. S. Calnek, L. Mazzella, S. Roser, J. Roman, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 52–57, 2003. View at Publisher · View at Google Scholar
  58. K. Goya, S. Sumitani, M. Otsuki et al., “The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells,” Journal of Diabetes and Its Complications, vol. 20, no. 5, pp. 336–342, 2006. View at Publisher · View at Google Scholar
  59. J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1810–1816, 2005. View at Publisher · View at Google Scholar
  60. A. Ptasinska, S. Wang, J. Zhang, R. A. Wesley, and R. L. Danner, “Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway,” The FASEB Journal, vol. 21, no. 3, pp. 950–961, 2007. View at Publisher · View at Google Scholar
  61. J. B. Majithiya, A. N. Paramar, and R. Balaraman, “Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats,” Cardiovascular Research, vol. 66, no. 1, pp. 150–161, 2005. View at Publisher · View at Google Scholar
  62. S. Fujishima, Y. Ohya, Y. Nakamura, U. Onaka, I. Abe, and M. Fujishima, “Troglitazone, an insulin sensitizer, increases forearm blood flow in humans,” The American Journal of Hypertension, vol. 11, no. 9, pp. 1134–1137, 1998. View at Publisher · View at Google Scholar
  63. U. Campia, L. A. Matuskey, and J. A. Panza, “Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors,” Circulation, vol. 113, no. 6, pp. 867–875, 2006. View at Publisher · View at Google Scholar
  64. M. N. Ghazzi, J. E. Perez, T. K. Antonucci et al., “Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group,” Diabetes, vol. 46, no. 3, pp. 433–439, 1997. View at Publisher · View at Google Scholar
  65. B. H. Sung, J. L. Izzo Jr., P. Dandona, and M. F. Wilson, “Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus,” Hypertension, vol. 34, no. 1, pp. 83–88, 1999. View at Google Scholar
  66. T. Murakami, S. Mizuno, K. Ohsato et al., “Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus,” The American Journal of Cardiology, vol. 84, no. 1, pp. 92–94, 1999. View at Publisher · View at Google Scholar
  67. A. I. Vinik, K. B. Stansberry, and P. M. Barlow, “Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus,” Journal of Diabetes and Its Complications, vol. 17, no. 5, pp. 279–285, 2003. View at Publisher · View at Google Scholar
  68. T. Nakamura, T. Matsuda, Y. Kawagoe et al., “Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients,” Metabolism, vol. 53, no. 10, pp. 1382–1386, 2004. View at Publisher · View at Google Scholar
  69. M. H. Voytovich, C. Simonsen, T. Jenssen, J. Hjelmesæth, A. Åsberg, and A. Hartmann, “Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients,” Nephrology Dialysis Transplantation, vol. 20, no. 2, pp. 413–418, 2005. View at Publisher · View at Google Scholar
  70. F. Pistrosch, K. Herbrig, B. Kindel, J. Passauer, S. Fischer, and P. Gross, “Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients,” Diabetes, vol. 54, no. 7, pp. 2206–2211, 2005. View at Publisher · View at Google Scholar
  71. K. Fujiwara, K. Hayashi, H. Matsuda et al., “Altered pressure-natriuresis in obese Zucker rats,” Hypertension, vol. 33, no. 6, pp. 1470–1475, 1999. View at Google Scholar
  72. A. D. Dobrian, S. D. Schriver, A. A. Khraibi, and R. L. Prewitt, “Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity,” Hypertension, vol. 43, no. 1, pp. 48–56, 2004. View at Publisher · View at Google Scholar
  73. R. Govers and T. J. Rabelink, “Cellular regulation of endothelial nitric oxide synthase,” The American Journal of Physiology, vol. 280, no. 2, pp. F193–F206, 2001. View at Google Scholar
  74. B. Braam and M. C. Verhaar, “Understanding eNOS for pharmacological modulation of endothelial function: a translational view,” Current Pharmaceutical Design, vol. 13, no. 17, pp. 1727–1740, 2007. View at Publisher · View at Google Scholar
  75. A. T. Gonon, A. Bulhak, F. Labruto, P.-O. Sjöquist, and J. Pernow, “Cardioprotection mediated by rosiglitazone, a peroxisome proliferator activated receptor gamma ligand, in relation to nitric oxide,” Basic Research in Cardiology, vol. 102, no. 1, pp. 80–89, 2007. View at Publisher · View at Google Scholar
  76. M. Ingbir, I. F. Schwartz, A. Shtabsky et al., “Rosiglitazone improves aortic arginine transport, through inhibition of PKCa, in uremic rats,” The American Journal of Physiology, vol. 295, no. 2, pp. F471–F477, 2008. View at Publisher · View at Google Scholar
  77. I. F. Schwartz, R. Ayalon, T. Chernichovski et al., “Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats,” Kidney International, vol. 69, no. 2, pp. 298–303, 2006. View at Publisher · View at Google Scholar
  78. L. Wagner, J. D. Klein, J. M. Sands, and C. Baylis, “Urea transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport,” The American Journal of Physiology, vol. 283, no. 3, pp. F578–F582, 2002. View at Publisher · View at Google Scholar
  79. S. Xiao, L. Wagner, J. Mahaney, and C. Baylis, “Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells,” The American Journal of Physiology, vol. 280, no. 6, pp. F989–F995, 2001. View at Google Scholar
  80. I. Inoue, S.-I. Goto, T. Matsunaga et al., “The ligands/activators for peroxisome proliferator-activated receptor a (PPARa) and PPAR? increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells,” Metabolism, vol. 50, no. 1, pp. 3–11, 2001. View at Publisher · View at Google Scholar
  81. J. Hwang, D. J. Kleinhenz, B. Lassègue, K. K. Griendling, S. Dikalov, and C. M. Hart, “Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production,” The American Journal of Physiology, vol. 288, no. 4, pp. C899–C905, 2005. View at Publisher · View at Google Scholar
  82. J. L. Mehta, B. Hu, J. Chen, and D. Li, “Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 12, pp. 2203–2208, 2003. View at Publisher · View at Google Scholar
  83. J. B. Majithiya, A. N. Parmar, C. J. Trivedi, and R. Balaraman, “Effect of pioglitazone on L-NAME induced hypertension in diabetic rats,” Vascular Pharmacology, vol. 43, no. 4, pp. 260–266, 2005. View at Publisher · View at Google Scholar
  84. P. A. Sarafidis and A. N. Lasaridis, “Actions of peroxisome proliferator-activated receptors-γ agonists explaining a possible blood pressure-lowering effect,” The American Journal of Hypertension, vol. 19, no. 6, pp. 646–653, 2006. View at Publisher · View at Google Scholar
  85. E. L. Schiffrin, “Role of endothelin-1 in hypertension and vascular disease,” The American Journal of Hypertension, vol. 14, no. 6, part 2, pp. 83S–89S, 2001. View at Publisher · View at Google Scholar
  86. F. Martin-Nizard, C. Furman, P. Delerive et al., “Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells,” Journal of Cardiovascular Pharmacology, vol. 40, no. 6, pp. 822–831, 2002. View at Publisher · View at Google Scholar
  87. H. Satoh, K. Tsukamoto, Y. Hashimoto et al., “Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR? on vascular endothelial function,” Biochemical and Biophysical Research Communications, vol. 254, no. 3, pp. 757–763, 1999. View at Publisher · View at Google Scholar
  88. P. Delerive, F. Martin-Nizard, G. Chinetti et al., “Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway,” Circulation Research, vol. 85, no. 5, pp. 394–402, 1999. View at Google Scholar
  89. T. Nakamura, C. Ushiyama, N. Shimada, K. Hayashi, I. Ebihara, and H. Koide, “Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients,” Journal of Diabetes and Its Complications, vol. 14, no. 5, pp. 250–254, 2000. View at Publisher · View at Google Scholar
  90. M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, “Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 45–51, 2003. View at Publisher · View at Google Scholar
  91. T. Münzel, U. Hink, T. Heitzer, and T. Meinertz, “Role for NADPH/NADH oxidase in the modulation of vascular tone,” Annals of the New York Academy of Sciences, vol. 874, pp. 386–400, 1999. View at Publisher · View at Google Scholar
  92. D. M. Tham, B. Martin-McNulty, Y.-X. Wang et al., “Angiotensin II is associated with activation of NF-?B-mediated genes and downregulation of PPARs,” Physiological Genomics, vol. 11, no. 1, pp. 21–30, 2003. View at Google Scholar
  93. Q. N. Diep, M. El Mabrouk, J. S. Cohn et al., “Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-?,” Circulation, vol. 105, no. 19, pp. 2296–2302, 2002. View at Publisher · View at Google Scholar
  94. U. Kintscher and T. Unger, “Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers,” Acta Diabetologica, vol. 42, supplement 1, pp. S26–S32, 2005. View at Publisher · View at Google Scholar
  95. N. Wang, L. Verna, N.-G. Chen et al., “Constitutive activation of peroxisome proliferator-activated receptor-? suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 34176–34181, 2002. View at Publisher · View at Google Scholar
  96. S. M. Jackson, F. Parhami, X.-P. Xi et al., “Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 9, pp. 2094–2104, 1999. View at Google Scholar
  97. Y. Jung, S. Song, and C. Choi, “Peroxisome proliferator activated receptor γ agonists suppress TNFα-induced ICAM-1 expression by endothelial cells in a manner potentially dependent on inhibition of reactive oxygen species,” Immunology Letters, vol. 117, no. 1, pp. 63–69, 2008. View at Publisher · View at Google Scholar
  98. N. Marx, F. Mach, A. Sauty et al., “Peroxisome proliferator-activated receptor-? activators inhibit IFN-?-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells,” The Journal of Immunology, vol. 164, no. 12, pp. 6503–6508, 2000. View at Google Scholar
  99. E. Imamoto, N. Yoshida, K. Uchiyama et al., “Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells,” BioFactors, vol. 20, no. 1, pp. 37–47, 2004. View at Publisher · View at Google Scholar
  100. A. Tesse, G. Al-Massarani, R. Wangensteen, S. Reitenbach, M. C. Martínez, and R. Andriantsitohaina, “Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 2, pp. 539–547, 2008. View at Publisher · View at Google Scholar
  101. E. Verrier, L. Wang, C. Wadham et al., “PPAR? agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase,” Circulation Research, vol. 94, no. 11, pp. 1515–1522, 2004. View at Publisher · View at Google Scholar
  102. S. H. Ramirez, D. Heilman, B. Morsey, R. Potula, J. Haorah, and Y. Persidsky, “Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes,” The Journal of Immunology, vol. 180, no. 3, pp. 1854–1865, 2008. View at Google Scholar
  103. V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh, “Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators,” Circulation, vol. 101, no. 3, pp. 235–238, 2000. View at Google Scholar
  104. C.-H. Wang, N. Ciliberti, S.-H. Li et al., “Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy,” Circulation, vol. 109, no. 11, pp. 1392–1400, 2004. View at Publisher · View at Google Scholar
  105. C. Gensch, Y. P. Clever, C. Werner, M. Hanhoun, M. Böhm, and U. Laufs, “The PPAR-γ agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells,” Atherosclerosis, vol. 192, no. 1, pp. 67–74, 2007. View at Publisher · View at Google Scholar
  106. F. Pistrosch, K. Herbrig, U. Oelschlaegel et al., “PPAR?-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells,” Atherosclerosis, vol. 183, no. 1, pp. 163–167, 2005. View at Publisher · View at Google Scholar
  107. C. Werner, C. H. Kamani, C. Gensch, M. Böhm, and U. Laufs, “The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance,” Diabetes, vol. 56, no. 10, pp. 2609–2615, 2007. View at Publisher · View at Google Scholar
  108. S. Redondo, M. Hristov, D. Gümbel, T. Tejerina, and C. Weber, “Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-γ and transforming growth factor-β1,” Thrombosis and Haemostasis, vol. 97, no. 6, pp. 979–987, 2007. View at Publisher · View at Google Scholar
  109. S. Verma, M. A. Kuliszewski, S.-H. Li et al., “C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease,” Circulation, vol. 109, no. 17, pp. 2058–2067, 2004. View at Publisher · View at Google Scholar
  110. T. Imanishi, K. Kobayashi, A. Kuroi, H. Ikejima, and T. Akasaka, “Pioglitazone inhibits angiotensin II-induced senescene of endothelial progenitor cell,” Hypertension Research, vol. 31, no. 4, pp. 757–765, 2008. View at Publisher · View at Google Scholar
  111. D. Bishop-Bailey, “Peroxisome proliferator-activated receptor β/δ goes vascular,” Circulation Research, vol. 102, no. 2, pp. 146–147, 2008. View at Publisher · View at Google Scholar
  112. L. Piqueras, A. R. Reynolds, K. M. Hodivala-Dilke et al., “Activation of PPARß/d induces endothelial cell proliferation and angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 63–69, 2007. View at Publisher · View at Google Scholar
  113. J. K. Han, H. S. Lee, H. M. Yang et al., “Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway,” Circulation, vol. 118, no. 10, pp. 1021–1033, 2008. View at Publisher · View at Google Scholar
  114. Y. Rival, N. Benéteau, T. Taillandier et al., “PPARa and PPARd activators inhibit cytokine-induced nuclear translocation of NF-?B and expression of VCAM-1 in EAhy926 endothelial cells,” European Journal of Pharmacology, vol. 435, no. 2-3, pp. 143–151, 2002. View at Publisher · View at Google Scholar